Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$8.19 +6.8%	$7.80	$6.85 ▼ $19.89	$483.82M	-0.08	359,247 shs	629,410 shs
CMPS COMPASS Pathways	$4.61 +7.0%	$3.95	$2.25 ▼ $8.54	$442.29M	2.17	1.79 million shs	2.36 million shs
KOD Kodiak Sciences	$10.20 +5.0%	$6.18	$1.92 ▼ $11.60	$538.78M	2.41	704,460 shs	669,916 shs
SCLX Scilex	$18.87 +10.1%	$10.61	$3.60 ▼ $45.15	$131.25M	1.32	313,464 shs	465,891 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	0.00%	+6.92%	-1.68%	+4.87%	-54.55%
CMPS COMPASS Pathways	0.00%	+6.71%	+5.49%	+5.73%	-34.52%
KOD Kodiak Sciences	0.00%	-3.50%	+23.64%	+196.51%	+265.59%
SCLX Scilex	0.00%	+4.37%	+76.03%	+314.73%	-56.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.7525 of 5 stars	3.5	0.0	0.0	2.0	1.7	0.6
CMPS COMPASS Pathways	2.2539 of 5 stars	3.4	3.0	0.0	1.8	0.8	0.6
KOD Kodiak Sciences	3.1932 of 5 stars	2.0	1.0	4.6	2.5	3.3	0.0
SCLX Scilex	2.4228 of 5 stars	3.3	2.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$26.80	227.23% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$16.29	253.27% Upside
KOD Kodiak Sciences	2.00	Hold	$11.75	15.20% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	2,311.23% Upside

Current Analyst Ratings Breakdown

Latest SCLX, CGEM, CMPS, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
8/18/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $28.00
8/18/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $5.00
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00
8/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
8/1/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$1.69 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$1.33 per share	N/A
SCLX Scilex	$44.24M	2.97	N/A	N/A	($35.80) per share	-0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	11/6/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.84	N/A	N/A	N/A	N/A	-87.89%	-57.77%	10/30/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-179.12%	N/A	-109.95%	N/A

Latest SCLX, CGEM, CMPS, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/13/2025	Q2 2025	SCLX Scilex	-$4.55	-$7.42	-$2.87	-$7.42	$26.25 million	$9.90 million
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.37	-$0.38	-$0.01	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	9.83	9.83
CMPS COMPASS Pathways	0.16	8.82	8.82
KOD Kodiak Sciences	N/A	3.48	3.48
SCLX Scilex	N/A	0.11	0.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
CMPS COMPASS Pathways	46.19%
KOD Kodiak Sciences	89.06%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
CMPS COMPASS Pathways	3.93%
KOD Kodiak Sciences	45.90%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	54.84 million	Optionable
CMPS COMPASS Pathways	120	95.94 million	92.17 million	Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable
SCLX Scilex	80	6.96 million	6.40 million	Optionable

SCLX, CGEM, CMPS, and KOD Headlines

Recent News About These Companies

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered ...

August 21 at 8:54 AM | theglobeandmail.com

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

August 21 at 8:54 AM | msn.com

Scilex Holding Company and Semnur Pharmaceuticals Announce $20 Million Private Placement for SP-102 Clinical Trial and Leadership Transition

August 21 at 6:31 AM | quiverquant.comQ

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulato

August 21 at 6:00 AM | globenewswire.com

Scilex (NASDAQ:SCLX) Releases Earnings Results, Misses Estimates By $2.87 EPS

August 15, 2025 | marketbeat.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral ...

August 15, 2025 | theglobeandmail.com

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

August 13, 2025 | globenewswire.com

Scilex (SCLX) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Scilex (NASDAQ:SCLX) Stock Price Up 3.7% - Time to Buy?

August 2, 2025 | marketbeat.com

Scilex Holding Co. (SCLX) Stock Price Today - WSJ

July 24, 2025 | wsj.com

SCLX Scilex Holding Company - Seeking Alpha

July 1, 2025 | seekingalpha.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25, 2025 | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX, CGEM, CMPS, and KOD Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$8.19 +0.52 (+6.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.46 +0.28 (+3.36%)

As of 08/22/2025 06:30 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

COMPASS Pathways NASDAQ:CMPS

$4.61 +0.30 (+6.96%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.02 (-0.43%)

As of 08/22/2025 07:53 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Kodiak Sciences NASDAQ:KOD

$10.20 +0.49 (+5.05%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.89 -0.31 (-3.04%)

As of 08/22/2025 05:22 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Scilex NASDAQ:SCLX

$18.87 +1.73 (+10.09%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$18.93 +0.06 (+0.34%)

As of 08/22/2025 07:57 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time